SLC5A2 and hydrops fetalis: Prior to the propensity score matching, the 1-month primary composite outcome of ACS/HF/all-cause mortality was significantly lower among the SGLT2 inhibitor users compared to the non-users as shown in Table 2 [6 (1.7%) vs. 13 (11.6%), HR 0.13 (0.05–0.35), p-value < 0.001].